TerminatedPhase 2

A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44

Stopped: Primary objective reached

Sweden45 participantsStarted 2017-11-28

Plain-language summary

Subjects referred for abdominal or thoracoabdominal CT-examination will be randomised to either the three contrast agents Lumentin® 44, Omnipaque® or Movprep. The difference in contrast density, as observed in the CT-examination, between lumen and wall (mucosal lining) will be compared by the three contrast agents.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects of either gender at least 18 years at the time of signing the informed consent. * Having a clinical indication for CT-examination of the abdomen Exclusion Criteria: * IV administration of iodine is contraindicated * Known allergy to egg albumen * Clinical suspicion, according to medical record, of fistula formation and/or leakage * Referral indication of small bowel disease(s) * Having known manifest thyrotoxicosis * Having known phenylketonuria * Having known Glucose-6-phosphatase deficiency

What they're measuring

Relative Mean Difference in Contrast Density

Timeframe: Day 1

Trial details

NCT IDNCT03326518

SponsorLument AB

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-09-30

Results submitted2020-05-11

View on ClinicalTrials.gov More Subjects Referred to CT-examination of the Abdomen trials